Detraxi to develop a new solution to reduce global blood shortages
Category: #health  By Nikita Chaurasia  Date: 2019-07-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Detraxi to develop a new solution to reduce global blood shortages

High income-growth countries like China will be the key recipient of the Detraxi biotechnology.

Detraxi, a biotechnology company, is reportedly planning to develop its proprietary biotechnology solution for a range of global health challenges to save millions of lives worldwide. Detraxi has been working in collaboration with some of the world’s most respected and talented scientists across diagnostics, fluid replacement, regenerative medicine and transplantation for the purpose.

Apparently, the biotechnology developed by Detraxi had previously went through numerous clinical trials and is presently undergoing new pre-clinical studies. High income-growth countries like China will be the key recipient of the Detraxi biotechnology. As population of China grows, the market for this technology will become increasingly significant.

Reportedly, in China, blood demand has been exceeding supply. Currently blood products have been able to satisfy only 50 percent of the entire demand. As per the World Health Organization (WHO), 0.92% of population in China have been donating blood, which falls between 1% to 3% rate.  This much rate of blood donation has been anticipated to be required to meet demand. The annual growth rate demand of clinical blood has been reported to be 10% -15%.

According to reliable sources, blood collection has doubled between 2011 and 2016 to 7000 tons. In 2018, 18.4 million units of blood were assigned throughout China. 15.8 million units were distributed within the same Province from where it was collected. But managing supplies of blood is immensely complex process. Refrigerated blood only stays usable for between 35-42 days.

Apparently, biotechnology is presently going through exponential technological development. It has been improving by a factor of 10 every year in terms of cost-benefit. This enhancement has been driving new biotech solutions which have not been made available before.

Sources cited, the progression of latest biotechnologies needs a very high inclination for risk and lots of patience. Detraxi is supported by Hong Kong and London-based technology billionaire Tej Kohli. Kohli reportedly considers that biotechnologies like Detraxi will offer solutions to some of the greatest public health challenges of the world.

Source credit: https://www.businesswire.com/news/home/20190721005001/en/Biotech-Company-Detraxi-Developing-Solution-Eliminate-Global

https://finance.yahoo.com/news/biotech-company-detraxi-developing-solution-000000870.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Australian researchers discover anti-parasite drug that kills COVID-19
Australian researchers discover anti-parasite drug that kills COVID-19
By Nikita Chaurasia

Researchers at Monash University, Melbourne, have reportedly announced that they discovered that an anti-parasite medicine can kill the novel strain of the coronavirus (SARS-CoV-2) that has currently brought the world to a standstill. In a study pub...

Trump calls for a $2 trillion budget for U.S. infrastructure growth
Trump calls for a $2 trillion budget for U.S. infrastructure growth
By Nikita Chaurasia

U.S. President Donald Trump has reportedly called for a $2 trillion spending budget to repair the and build new and currently crumbling infrastructure including tunnels, bridges, and roads, seizing on the COVID-19 outbreak as well as interest rates t...

Analytics 4 Life reveals new data backing novel method to predict LVEDP
Analytics 4 Life reveals new data backing novel method to predict LVEDP
By Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiology) 69th Annual Scientific Sessi...